title: [Efficacy of periurethral injections of polyacrylamide hydrogel (Bulkamid(®)) and quality of life of patients with urinary incontinence due to sphincter deficiency (IUE-IS)].
abstract: BACKGROUND
  This study was carried out to evaluate the efficacy of periurethral injection of polyacrylamide hydrogel (PAHG, Bulkamid(®), Ethicon) for the treatment of female stress urinary incontinence (SUI).
  
  
  METHODS
  Single-center prospective study: periurethral injection of Bulkamid(®) was performed in 80 patients with severe urinary incontinence between June 2010 and October 2011. The evaluation of the impact on quality of life was carried out using the Patient Global Impression of Severity (PGI-S), the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) and Patient Global Impression of Improvement (PGI-I) before and after treatment.
  
  
  RESULTS
  With a mean follow-up of 18.6 ± 5.3 months, 60% of patients had improved. For 30/74 (40%) there was no improvement and no patient had worsening of PGI-I after injection. Before surgery, 55.4% of patients considered their condition as severe (PGI-S). After injecting 21/74 (28%) and 11/74 (15%) considered it normal and severe (zero leakage). The ICIQ -SF score increased from 17 ± 2.84 before injection to 13 ± 5.52 after surgery, with a significant 30% decrease (P<0.00001). The reinjection rate was 29%. The complication rate was 16% (17/108): 11 cases of transient postoperative retention, 2 cases of cystitis, dysuria four episodes. No abscess or infection at the injection site, no specific complication to the product used.
  
  
  CONCLUSIONS
  With an (PGI-I) improvement rate of 60 and 15% of patients without leakage (PGI-S/ICIQ), periurethral injection of Bulkamid(®) is an effective and safe treatment option for women with a severe urinary incontinence especially in therapeutic failure.
  
  
  METHODS
  4.
authors.affiliation: Service d'urologie et d'andrologie, hôpital universitaire Caremeau, CHU de Nîmes, place du Professeur-R.-Debré, 30029 Nîmes cedex 9, France. Electronic address: alexberaru@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Beraru
authors.affiliation: Service d'urologie et d'andrologie, hôpital universitaire Caremeau, CHU de Nîmes, place du Professeur-R.-Debré, 30029 Nîmes cedex 9, France.
authors.forename: S
authors.initials: S
authors.lastname: Droupy
authors.affiliation: Service d'urologie et d'andrologie, hôpital universitaire Caremeau, CHU de Nîmes, place du Professeur-R.-Debré, 30029 Nîmes cedex 9, France.
authors.forename: L
authors.initials: L
authors.lastname: Wagner
authors.affiliation: Service d'urologie et d'andrologie, hôpital universitaire Caremeau, CHU de Nîmes, place du Professeur-R.-Debré, 30029 Nîmes cedex 9, France.
authors.forename: L
authors.initials: L
authors.lastname: Soustelle
authors.affiliation: Service d'urologie et d'andrologie, hôpital universitaire Caremeau, CHU de Nîmes, place du Professeur-R.-Debré, 30029 Nîmes cedex 9, France.
authors.forename: C
authors.initials: C
authors.lastname: Muyschondt
authors.affiliation: Service d'urologie et d'andrologie, hôpital universitaire Caremeau, CHU de Nîmes, place du Professeur-R.-Debré, 30029 Nîmes cedex 9, France.
authors.forename: K
authors.initials: K
authors.lastname: Ben Naoum
authors.affiliation: Service d'urologie et d'andrologie, hôpital universitaire Caremeau, CHU de Nîmes, place du Professeur-R.-Debré, 30029 Nîmes cedex 9, France.
authors.forename: P
authors.initials: P
authors.lastname: Grés
authors.affiliation: Service d'urologie et d'andrologie, hôpital universitaire Caremeau, CHU de Nîmes, place du Professeur-R.-Debré, 30029 Nîmes cedex 9, France.
authors.forename: M
authors.initials: M
authors.lastname: Boukaram
authors.affiliation: Service d'urologie et d'andrologie, hôpital universitaire Caremeau, CHU de Nîmes, place du Professeur-R.-Debré, 30029 Nîmes cedex 9, France.
authors.forename: P
authors.initials: P
authors.lastname: Costa
mesh_terms: D000180:Acrylic Resins / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001672:Biocompatible Materials / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020100:Hydrogels / Q000627:therapeutic use*; D007267:Injections; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life; D019233:Retreatment / Q000706:statistics & numerical data; D014521:Urethra / Q000503:physiopathology; D014550:Urinary Incontinence, Stress / Q000503:physiopathology / Q000628:therapy*
chemical_list: D000180:Acrylic Resins; D001672:Biocompatible Materials; C528271:Bulkamid; D020100:Hydrogels
keywords: Bulkamid(®); Incontinence urinaire; Injection péri-urétrale; Periurethral injection; Polyacrylamide hydrogel; Urinary incontinence